Featured Research

from universities, journals, and other organizations

Vaccine for metastatic breast, ovarian cancer shows promise

Date:
November 30, 2011
Source:
American Association for Cancer Research
Summary:
Treatment with a recombinant poxviral vaccine showed a positive response in both metastatic breast cancer and ovarian cancer, according to a recent trial.

Treatment with a recombinant poxviral vaccine showed a positive response in both metastatic breast cancer and ovarian cancer, according to a trial published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Related Articles


"With this vaccine, we can clearly generate immune responses that lead to clinical responses in some patients," said lead researcher James Gulley, M.D., Ph.D., director and deputy chief of the clinical trials group at the Laboratory of Tumor Immunology and Biology at the National Cancer Institute.

Gulley and colleagues enrolled 26 patients and assigned them to monthly vaccinations with the PANVAC vaccine, which contains transgenes for MUC-1, CEA and three T cell costimulatory molecules.

These patients were already heavily pretreated, with 21 of them receiving at least three prior chemotherapy regimens.

Among the 12 patients with breast cancer, median time to progression was 2.5 months and median overall survival was 13.7 months. Four patients had stable disease.

For the 14 patients with ovarian cancer, median time to progression was two months and median overall survival was 15 months.

Following treatment, mild injection-site reactions were the most common side effect.

According to Gulley, interest in cancer vaccines is increasing and more study is needed to determine which vaccines will benefit which patients. "The sustained benefit seen in some patients in this study underscores the potential for therapeutic vaccines to impact clinical outcomes without toxicity," he said. "However, more studies in the appropriate patient populations are required to adequately assess efficacy."

The study was funded by the National Cancer Institute.


Story Source:

The above story is based on materials provided by American Association for Cancer Research. Note: Materials may be edited for content and length.


Journal Reference:

  1. M. Mohebtash, K.-Y. Tsang, R. A. Madan, N.-Y. Huen, D. J. Poole, C. Jochems, J. Jones, T. Ferrara, C. R. Heery, P. M. Arlen, S. M. Steinberg, M. Pazdur, M. Rauckhorst, E. C. Jones, W. L. Dahut, J. Schlom, J. L. Gulley. A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer. Clinical Cancer Research, 2011; 17 (22): 7164 DOI: 10.1158/1078-0432.CCR-11-0649

Cite This Page:

American Association for Cancer Research. "Vaccine for metastatic breast, ovarian cancer shows promise." ScienceDaily. ScienceDaily, 30 November 2011. <www.sciencedaily.com/releases/2011/11/111108132903.htm>.
American Association for Cancer Research. (2011, November 30). Vaccine for metastatic breast, ovarian cancer shows promise. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2011/11/111108132903.htm
American Association for Cancer Research. "Vaccine for metastatic breast, ovarian cancer shows promise." ScienceDaily. www.sciencedaily.com/releases/2011/11/111108132903.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins